Wall Street analyst estimates for Jaguar Health, Inc. (JAGX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health.
Valuation Ratios
| Price / Book | 0.03 |
| EV / EBITDA | -0.25 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $141523 | $4.4M | $4.4M | $5.8M | $9.4M | $4.3M | $12.0M | $9.8M | $11.7M | $11.5M |
| Cost of Revenue | $51966 | $880405 | $2.8M | $3.8M | $3.3M | $2.3M | $2.0M | $2.0M | $2.0M | $3.8M |
| Gross Profit | $89557 | $3.5M | $1.7M | $2.0M | $6.1M | $2.0M | $9.9M | $7.7M | $9.7M | $7.7M |
| Research & Development | $7.2M | $4.3M | $5.2M | $5.8M | $6.4M | $15.1M | $17.6M | $18.6M | $16.5M | $25.0M |
| Selling, General & Admin | $6.5M | $14.3M | $22.1M | $20.4M | $21.0M | $26.0M | $26.7M | $23.0M | $24.0M | $26.0M |
| Operating Expenses | $13.7M | $18.6M | $27.3M | $30.9M | $32.8M | $42.7M | $44.4M | $42.0M | $40.6M | $52.8M |
| Operating Income | -$13.6M | -$34.2M | -$30.8M | -$28.9M | -$26.6M | -$40.7M | -$34.4M | -$34.3M | -$30.8M | -$45.1M |
| EBITDA | -$13.7M | -$11.1M | -$27.8M | -$30.9M | -$28.7M | -$42.4M | -$33.4M | -$32.8M | -$36.7M | -$51.7M |
| Interest Expense | $985549 | $1.2M | $2.6M | $5.7M | $2.8M | $8.4M | $12.7M | $6.4M | $231000 | -$67000 |
| Pre-tax Income | -$14.7M | -$35.1M | -$32.1M | -$38.5M | -$33.8M | -$52.6M | -$48.4M | -$41.9M | -$39.3M | -$54.0M |
| Income Tax | 0 | -$13.2M | 0 | $10000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$14.7M | -$22.0M | -$32.1M | -$38.5M | -$33.8M | -$52.6M | -$47.5M | -$41.3M | -$38.5M | -$53.4M |
| EPS | $-16744218756.00 | $-6325593752.00 | $-1810550318.00 | $-106403456.00 | $-11814153.00 | $-4631759.00 | $-1899528.00 | $-93992.00 | $-4574.07 | $-803.95 |
| EPS (Diluted) | $-16744218756.00 | $-6325593752.00 | $-1810550318.00 | $-106403456.00 | $-11814153.00 | $-4631759.00 | $-1899528.00 | $-93992.00 | $-4574.07 | $-803.95 |
| Shares Outstanding (Diluted) | 0 | 0 | 0 | 0 | $3 | $11 | $25 | $439 | $8415 | $66640 |
Price
| Price | $0.23 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BDRX · CANF · CLDI · CNSP · GNPX · GRI · INM
Explore sector: Healthcare · Biotechnology
More sections of JAGX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks